JP2014520759A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520759A5
JP2014520759A5 JP2014517338A JP2014517338A JP2014520759A5 JP 2014520759 A5 JP2014520759 A5 JP 2014520759A5 JP 2014517338 A JP2014517338 A JP 2014517338A JP 2014517338 A JP2014517338 A JP 2014517338A JP 2014520759 A5 JP2014520759 A5 JP 2014520759A5
Authority
JP
Japan
Prior art keywords
cancer
individual
receptor
composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520759A (ja
JP6305920B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2012/000795 external-priority patent/WO2013003895A1/en
Publication of JP2014520759A publication Critical patent/JP2014520759A/ja
Publication of JP2014520759A5 publication Critical patent/JP2014520759A5/ja
Application granted granted Critical
Publication of JP6305920B2 publication Critical patent/JP6305920B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517338A 2011-07-01 2012-07-02 併用療法 Active JP6305920B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011902623 2011-07-01
AU2011902623A AU2011902623A0 (en) 2011-07-01 Combination therapy
PCT/AU2012/000795 WO2013003895A1 (en) 2011-07-01 2012-07-02 Combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018039564A Division JP6490270B2 (ja) 2011-07-01 2018-03-06 併用療法

Publications (3)

Publication Number Publication Date
JP2014520759A JP2014520759A (ja) 2014-08-25
JP2014520759A5 true JP2014520759A5 (https=) 2015-08-20
JP6305920B2 JP6305920B2 (ja) 2018-04-04

Family

ID=47436374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014517338A Active JP6305920B2 (ja) 2011-07-01 2012-07-02 併用療法
JP2018039564A Active JP6490270B2 (ja) 2011-07-01 2018-03-06 併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018039564A Active JP6490270B2 (ja) 2011-07-01 2018-03-06 併用療法

Country Status (11)

Country Link
US (3) US9566318B2 (https=)
EP (1) EP2726095B1 (https=)
JP (2) JP6305920B2 (https=)
CN (1) CN103702683B (https=)
AU (1) AU2012278921B2 (https=)
BR (1) BR112013033974A2 (https=)
CA (1) CA2840251C (https=)
ES (1) ES2689272T3 (https=)
MX (1) MX349321B (https=)
WO (1) WO2013003895A1 (https=)
ZA (1) ZA201400120B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性p2x7レセプター抗体、癌及びその他の容態の診断及び処置
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
US8933263B2 (en) 2010-12-29 2015-01-13 Ecolab Usa Inc. Water temperature as a means of controlling kinetics of onsite generated peracids
US8846107B2 (en) 2010-12-29 2014-09-30 Ecolab Usa Inc. In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
EP3766523A1 (en) 2014-12-18 2021-01-20 Ecolab USA Inc. Generation of peroxyformic acid through polyhydric alcohol formate
EP3232781A4 (en) 2014-12-18 2018-08-22 Ecolab USA Inc. Methods for forming peroxyformic acid and uses thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
EP3841059A1 (en) 2018-08-22 2021-06-30 Ecolab USA Inc. Hydrogen peroxide and peracid stabilization with molecules based on a pyridine carboxylic acid at c-3, -4 or -5
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトP2x4レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性p2x7レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
GB0419295D0 (en) * 2004-08-31 2004-09-29 Genomica Sau Methods and compositions to prevent neuronal degeneration
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性p2x7受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) * 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
KR20170097234A (ko) * 2008-12-10 2017-08-25 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) * 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US8828944B2 (en) * 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Similar Documents

Publication Publication Date Title
JP2014520759A5 (https=)
JP6490270B2 (ja) 併用療法
ES2987034T3 (es) Anticuerpos anti-PD-L1
JP2013531970A5 (https=)
HRP20200591T1 (hr) Protutijela specifična za klaudin 6 (cldn6)
JP2018070648A5 (https=)
JP7249696B2 (ja) 抗cldn抗体並びにその医薬組成物および検出方法
JP2013534515A5 (ja) 受容体型チロシンキナーゼc−Metに対する抗体
JP2020501531A5 (https=)
JP2017519759A5 (https=)
JP2022513053A5 (https=)
JP2013502913A5 (https=)
JP2012522523A5 (https=)
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
JP2015534579A5 (https=)
JP2017500028A5 (https=)
BR112014006175B1 (pt) Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
BR112020014848A2 (pt) Anticorpo anti-4-1bb, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
JP2015503909A5 (https=)
CN110072892A (zh) Mg7,高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
WO2022171134A1 (zh) 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途
CN110678753B (zh) 用于治疗肺癌的组合物和方法
JP2020505075A5 (https=)
CN114040776A (zh) Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
JP2015518824A5 (https=)